Recurrent Transformed Chronic Lymphocytic Leukemia Clinical Trials

12 clinical trials for Recurrent Transformed Chronic Lymphocytic Leukemia across international registries, including 6 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma — RECRUITING · PHASE2
• CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies — RECRUITING · PHASE1
• Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies — RECRUITING · PHASE1
• Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome — RECRUITING · PHASE2
• B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies — RECRUITING · PHASE1
• Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation — RECRUITING · PHASE1
• Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome — ACTIVE_NOT_RECRUITING · PHASE2
• Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia — SUSPENDED · PHASE1
• A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas — ACTIVE_NOT_RECRUITING · PHASE1
• Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation — ACTIVE_NOT_RECRUITING · PHASE2
• Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies — TERMINATED · PHASE1
• Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma — WITHDRAWN · PHASE2

Refine this search